Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review

키워드

참고문헌 (46)

1. "Medicare Part D Drug Spending Dashboard" (2021)[URL]
2. Duan Y, "Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia", Pharmacoepidemiol Drug Saf, 27, pp.340~348 (2018)
3. Tae BS, "Alpha-blocker and risk of dementia in patients with benign prostatic hyperplasia : a nationwide population based study using the National Health Insurance Service Database", J Urol, 202, pp.362~368 (2019)
4. Sohn JH, "The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia : a study using the Hallym Smart Clinical Data Warehouse", Medicine(Baltimore), 99, pp.e20240~ (2020)
5. Caine M, "The use of alpha-adrenergic blockers in benign prostatic obstruction", Br J Urol, 48, pp.255~263 (1976)
6. Lepor H, "Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia", Urology, 32(6 Suppl), pp.21~26 (1988)
7. Lerner LB, "Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia : AUA GUIDELINE PART I-Initial work-up and medical management", J Urol, 206, pp.806~817 (2021)
8. Shimohama S, "Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia", J Neurochem, 47, pp.1295~1301 (1986)
9. Palacios JM, "Alpha 1-adrenoceptors in the mammalian brain : similar pharmacology but different distribution in rodents and primates", Brain Res, 419, pp.65~75 (1987)
10. Szot P, "Alpha1-adrenoreceptor in human hippocampus : binding and receptor subtype mRNA expression", Brain Res Mol Brain Res, 139, pp.367~371 (2005)
11. in combined hippocampal-entorhinal cortex slices : modulation by receptors for norepinephrine and N-methyl-D-aspartate, "Epilepsy Res", 1987, 53~62
12. Papay R, "Localization of the mouse alpha1A-adrenergic receptor(AR)in the brain : alpha1AAR is expressed in neurons, GABAergic interneurons, and NG2 oligodendrocyte progenitors", J Comp Neurol, 497, pp.209~222 (2006)
13. Kotzbauer PT, "Lewy body pathology in Alzheimer’s disease", J Mol Neurosci, 17, pp.225~232 (2001)
14. Doze VA, "Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity", Mol Pharmacol, 80, pp.747~758 (2011)
15. Collette KM, "Long-term alpha1B-adrenergic receptor activation shortens lifespan, while alpha1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence", Age(Dordr), 36, pp.9675~ (2014)
16. Rokosh DG, "Knockout of the alpha 1A", C-adrenergic receptor subtype : the alpha 1A, Proc Natl Acad Sci U S A, pp.2002, 99[DOI]
17. Kim CH, "Alpha1-adrenoceptor antagonists improve memory by activating Nmethyl-D-aspartate-induced ion currents in the rat hippocampus", Int Neurourol J, 19, pp.228~236 (2015)
18. Weber MA, "Glycolysis-enhancing alpha(1)-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease", NPJ Parkinsons Dis, 9, pp.32~ (2023)
19. Perez DM, "Alpha(1)-adrenergic receptors in neurotransmission, synaptic plasticity, and cognition", Front Pharmacol, 11, pp.581098~ (2020)
20. Crook T, "Noradrenergic intervention in Alzheimer’s disease", Psychopharmacol Bull, 28, pp.67~70 (1992)
21. Mohr E, "Clonidine treatment of Alzheimer’s disease", Arch Neurol, 46, pp.376~378 (1989)
22. Riekkinen M, "Clonidine impairs sustained attention and memory in Alzheimer’s disease", Neuroscience, 92, pp.975~982 (1999)
23. Barcelos NM, "Guanfacine treatment for prefrontal cognitive dysfunction in older participants : a randomized clinical trial", Neurobiol Aging, 70, pp.117~124 (2018)
24. "Veritas health innovation"[URL]
25. Schünemann HJ, "Cochrane Handbook for Systematic Reviews of Interventions", pp.375~402 (2019), John Wiley & Sons
26. Slim K, "Methodological index for non-randomized studies(minors) : development and validation of a new instrument", ANZ J Surg, 73, pp.712~716 (2003)
27. Norgaard M, "Sleep disruption and Alzheimer’s disease risk : inferences from men with benign prostatic hyperplasia", EClinicalMedicine, 32, pp.100740~ (2021)
28. Wang LY, "Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression", Am J Geriatr Psychiatry, 17, pp.744~751 (2009)
29. Kosilov K, "Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage", Aging Male, 21, pp.121~129 (2018)
30. Kosilov K, "The analysis of the effects of executive functions, working memory and other factors on medication adherence in elderly men with benign prostatic hyperplasia and overactive bladder symptoms", Curr Aging Sci, 13, pp.72~80 (2020)
31. Coindreau-Frías F, "Factors associated with cognitive performance in residents of long-term care facilities in Northeast Mexico", Arch Neurocien, 26, pp.10~19 (2021)
32. Latvala L, "Use of alpha1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer’s disease", Pharmacoepidemiol Drug Saf, 31, pp.1110~1120 (2022)
33. Frankel JK, "Is tamsulosin linked to dementia in the elderly?", Curr Urol Rep, 19, pp.69~ (2018)
34. Andrade C, "How to read a research paper : an exercise in critical thinking in the context of an epidemiologic study on tamsulosin and the risk of dementia", J Clin Psychiatry, 79, pp.18~ (2018)
35. Rouquier L, "Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum : a microdialysis study", Eur J Pharmacol, 261, pp.59~64 (1994)
36. Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics, "J Pharmacol Exp Ther", 1999, 1575~1583
37. Yamada S, "In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues", J Pharmacol Exp Ther, 296, pp.160~167 (2001)
38. Okura T, "Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats", J Pharm Pharmacol, 54, pp.975~982 (2002)
39. Hattori T, "Emotional stress facilitates micturition reflex : possible inhibition by an alpha1-adrenoceptor blocker in the conscious and anesthetized state", Int Neurourol J, 23, pp.100~108 (2019)
40. Cai Z, "Role of Blood-Brain Barrier in Alzheimer’s disease", J Alzheimers Dis, 63, pp.1223~1234 (2018)
41. Andjelkovic AV, "Blood-Brain Barrier dysfunction in normal aging and neurodegeneration : mechanisms, impact, and treatments", Stroke, 54, pp.661~672 (2023)
42. Waardenburg IE, "Delirium caused by urinary retention in elderly people : a case report and literature review on the"cystocerebral syndrome"", J Am Geriatr Soc, 56, pp.2371~2372 (2008)
43. Skelly J, "Urinary incontinence associated with dementia", J Am Geriatr Soc Coind, 43, pp.286~294 (1995)
44. Grant RL, "First diagnosis and management of incontinence in older people with and without dementia in primary care : a cohort study using The Health Improvement Network primary care database", PLoS Med, 10, pp.e1001505~ (2013)
45. Guarnieri B, "Sleep and cognitive decline : a strong bidirectional relationship. It is time for specific recommendations on routine assessment and the management of sleep disorders in patients with mild cognitive impairment and dementia", Eur Neurol, 74, pp.43~48 (2015)
46. Bubu OM, "Sleep, cognitive impairment, and Alzheimer’s disease : a systematic review and meta-analysis", Sleep, 40(1) (2017)

관련 논문AI추천